血小板活化因子在药源性严重过敏反应中的研究现状  

Advance of platelet activating factor in drug-induced anaphylaxis

作　　者：马翔[1] 李潇潇[1] 刘维[1] 翟所迪[1] 

机构地区：[1]北京大学第三医院药剂科,北京100191

出　　处：《中国临床药理学杂志》2015年第4期308-311,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(81141123)

摘　　要：药源性严重过敏反应有难以预测、发作突然和致命性等特点,从而成为困扰临床药物使用的重要安全性因素。由于目前尚无严格的随机对照试验支持抢救药物的推荐,医生常根据临床经验用肾上腺素、抗组胺药和/或糖皮质激素应对突发的药源性严重过敏反应。血小板活化因子(PAF)信号通路可为研究药源性严重过敏反应提供崭新的视角。本文将就药源性严重过敏反应的临床和流行病学特点、PAF通路、抗PAF通路的药物等进行概述。The acute unpredictably life- threatening characteristic of drug- induced anaphylaxis hinders the safe use of clinical medication. In the absence of rigid randomized controlled trials supporting the recommendations for the treatment of immediate onset, doctors often treat drug- induced anaphylaxis with epinephrine, antihistamines and / or glucocorticoids. The researches in platelet activating factor signaling pathway could provide a novel perspective for drug- induced anaphylaxis. This review will briefly introduce the clinical and epidemiological characteristics of drug- induced anaphylaxis,platelet activating factor pathway and drugs targeting at this pathway.

关 键 词：药源性严重过敏反应 血小板活化因子 血小板活化因子乙酰水解酶 

分 类 号：R558[医药卫生—血液循环系统疾病] R781.67[医药卫生—内科学]